Healthcare >> CEO Interviews >> March 29, 2004


HOWARD C. BIRNDORF is Chairman, Chief Executive Officer and Founder of Nanogen, Inc. He has served as Chairman of the Board since 1993 and from 1993 to April 2001 served as Chief Executive Officer. Mr. Birndorf was a co-Founder and Chairman Emeritus of Ligand Pharmaceuticals, Incorporated, where from January 1988 to November 1991 he was President and Chief Executive Officer. He was also a co-Founder, Director and Executive Vice President of Gen-Probe Incorporated, co-Founder and Vice President of Corporate Development at Hybritech, Incorporated, co- Founder and Director of IDEC Pharmaceuticals Corporation and was involved in the formation of Gensia Pharmaceuticals, Inc. (currently known as Sicor Inc.) where he was a founding Director. From November 1991 to September 1993, Mr. Birndorf was President of Birndorf Technology Development, an investment and consulting company. He was a founding Director of Neurocrine Biosciences, Inc., and served as Director from 1992 through 1997, and is a founding Director of Graviton, Inc. Mr. Birndorf is currently a Director of the Cancer Center of the University of California, San Diego. He received a BA in Biology from Oakland University, an MS in Biochemistry from Wayne State University and received an honorary Doctor of Science degree from Oakland University in 1999. Profile
TWST: Could you give us a general introduction to Nanogen?

Mr. Birndorf: Nanogen was started over 10 years ago with a vision to

develop and commercialize diagnostic tools and services to